Bio-Nano Sensium Technologies, a subsidiary of Advance Nanotech, Inc., (OTC BB:AVNA.OB), today announced a limited beta test program of its wireless biosensor system. Under terms of the program, beta-stage versions of Bio-Nano Sensium (BNS) system will be available to potential partners and customers for evaluation. Wireless biosensors are increasingly seen as a desirable treatment for a range of chronic conditions including diabetes, cardiac conditions and asthma.

The BNS system is based on a ground-breaking low-cost, disposable integrated sensor interface chip - the Sensium - that, due to its ultra low power and very small battery size, can be implanted in or worn on the body with complete freedom of movement unlike existing bulky monitoring solutions. The Sensium is compatible with a wide range of sensors and can be configured to detect vital signs such as ECG, blood oxygen and glucose, body temperature, and even motion and mobility. The BNS system is designed to enhance the way doctors and patients monitor a host of chronic illnesses, increasing the effectiveness of available treatments and improving the quality of life for patients.

The company's beta program serves a dual purpose. For prospective customers, the program offers the opportunity evaluate a working model of the BNS system. For BNS and Advance Nanotech partners and system integrators, the beta program provides a working platform for obtaining configuration data, developing control and calibration algorithms for bio-nano sensors, and optimizing wireless operating protocols for specific applications. Trials of the fully integrated BNS system are planned for the second quarter of 2006.

"As BNS technology becomes commercially available we anticipate a wide range of applications across the healthcare industry. Some of these applications will be developed by BNS and Advance Nanotech, others will be developed in partnership with outside organizations," said Stephanie Interbartolo, Senior Vice-President of Business Development for Advance Nanotech. "We encourage collaboration, and welcome the chance to demonstrate the technology to potential partners."

Bio-Nano Sensium Technologies is a joint venture between Advance Nanotech, Inc. and Toumaz Technology Ltd., a UK-based developer of advanced radio frequency (RF), analog and mixed signal semiconductors. The BNS technology holds great promise for integration in bio-nanosystems, where final product devices must be small, low-power, possess on-board processing capability and incorporate wireless communications.

About Toumaz Technology Ltd.

Toumaz Technology Limited is a developer of advanced RF, analogue and mixed signal semiconductors. The focus of the business is low power devices based on the company's proprietary AMx(tm) (Advanced Mixed Signal) technology which addresses the needs of lower power consumption for mobile and wirelessly connected systems.

About Advance Nanotech, Inc.

Advance Nanotech Inc. is dedicated to ensuring nanotechnology discoveries reach maximum market potential through successful commercialization. Advance is the trusted guide to commercial success for nanotech entrepreneurs spanning the globe, partnering with leading universities to provide scientists and researchers with mission critical infrastructure support to transform their discoveries to marketable solutions. The organization provides a range of services and support including financing, leadership assets and counsel on intellectual property, licensing and regulatory issues. With a portfolio of nearly 20 companies developing technologies which offer potentially breakthrough nanotechnology discoveries in the electronics, biopharma and materials sectors, Advance's goal is to transform the potential for nanotechnology discoveries into innovative products that further evolve existing industries and enable new markets.

This document contains forward-looking statements by Advance Nanotech regarding its expectations as to its business, and involves risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements.

Factors that may cause such a difference include, but are not limited to, problems and risks associated with developments in the nanotechnology industry in general and in Advance Nanotech's products under development in particular; the potential failure of Advance Nanotech's products under development to prove safe and effective in application; uncertainties inherent in the early stage of Advance Nanotech's products under development; failure to successfully implement or complete research programmes; failure to receive marketing clearance from regulatory agencies for our products under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Advance Nanotech's business, structure or projections; the development of competing products; uncertainties related to Advance Nanotech 's dependence on third parties and partners; and those risks described Advance Nanotech 's filings with the SEC. Advance Nanotech disclaims any obligation to update these forward-looking statements.

Further information about these and other relevant risks and uncertainties may be found in the Advance Nanotech's findings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.

Public Relations:
Racepoint Group
RJ Bardsley, 781-487-4616
rbardsley@racepointgroup.com
or
Investor Relations Contact:
CEOCast
Cormac Glynn, 212-732-4300
cglynn@ceocast.com